Poland· PL-100410539

Xylo-Pantenol

A xylometazoline product containing xylometazolini hydrochloridum + dexpanthenolum, registered in Poland by Teva B.V.. The same ATC class is registered in 10 of our 19 countries.

ATC R01AB06

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedXylo-PantenolATCR01AB06REGISTER NO.PL-100410539PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Xylometazoline is registered in 10 of 19 countries.

Countries holding a registration under ATC R01AB06 (xylometazoline), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose

Xylometazoline · ATC R01AB06

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Xylometazolini hydrochloridum + Dexpanthenolum
Manufacturer
Teva B.V.
Country
Poland (PL)
ATC code
R01AB06
ATC class
Xylometazoline
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909991463717

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

63 interactions on record for xylometazoline.

Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Xylometazoline · interactions on record

63 records

  • 6 severe
  • 54 moderate

Most severe, free to view

  • MethylergometrineG02AB01severe
  • DihydroergotamineN02CA01severe
  • ErgotamineN02CA02severe
  • MethysergideN02CA04severe

3 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Xylometazoline in 7 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All xylometazoline products

Authorised across Europe · EMA

The same active substance is authorised in 23 EEA countries. Names it is sold under:

  • Austria · Nasic, Nasic Pur
  • Bulgaria · Nasic назик, Ксилазол
  • Cyprus · Hexarhinal Plus, Hexarhinal Plus Kids
  • Czechia · Nasic, Olynth Plus
  • Germany · Nasenduo Kinder, Nasic
  • Denmark · Zymelin Care
  • Estonia · Otrinazil, Septanazal
  • Spain · Septanasal
  • Finland · Septanazal
  • United Kingdom (Northern Ireland) · Sudafed Plus Blocked Nose
  • Greece · Hexarhinal Plus, Hexarhinal Plus Kids
  • Croatia · Ksilometazolin/Dekspantenol Pliva, Nasic
  • Hungary · Actifed, Actifed Kid
  • Ireland · Septanazal, Septanazal For Children
  • Lithuania · Galathenal, Olydex
  • Luxembourg · Nasenduo Nasenspray Kinder, Xyloduo Nasenspray
  • Latvia · Galathenal, Olydex
  • Malta · Septanazal
  • Norway · Xylodex
  • Portugal · Nasex Duo, Septanazal Para Adultos
  • Romania · Bixtonim Xylo Duo, Nasic
  • Slovenia · Nasic, Olynth Combo
  • Slovakia · Nasal Duo Active, Nasic

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f8cc70c6-5a13-4446-9b88-fa5102bb1052
GET /v1/drugs/f8cc70c6-5a13-4446-9b88-fa5102bb1052?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Aerozol do nosa, roztwór",
  "source": "urpl",
  "strength": "(1 mg + 50 mg)/ml",
  "packaging": "05909991463717 ¦ OTC ¦ 141670\n1 butelka 10 ml",
  "substance": "Xylometazolini hydrochloridum 1 mg/ml + Dexpanthenolum 50 mg/ml",
  "common_name": "Xylometazolini hydrochloridum + Dexpanthenolum",
  "pl_product_id": "100410539",
  "pozwolenie_nr": "26596",
  "auth_procedure": "DCP",
  "authorisation_validity": "Bezterminowe"
}

See everything about xylometazoline.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.